The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Advocates have claimed that CVS’s refusal to cover Yeztugo violates the Affordable Care Act (ACA), which requires insurers to ...

CVS Health, one of the nation’s largest pharmacy benefit manager companies that play a lead role in deciding which drugs are ...

HIV experts are concerned that Yeztugo’s full potential might remain unrealized. Priced at $14,109 per injection, or $2,352 per month, Yeztugo's cost could be another hurdle.

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero HIV infections.

HIV- 1 resistance substitutions may emerge in individuals with undiagnosed HIV-1 infection taking only Yeztugo, because Yeztugo alone is not a complete regimen for HIV-1 treatment.

JACKSON, Miss. — The FDA has approved Yeztugo, the world’s first twice-a-year shot to prevent HIV infection, marking a significant advancement in HIV prevention. The new treatment is expected to be a ...